Ensign Peak Advisors
SNDX icon

Ensign Peak Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Ensign Peak Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19M Sell
867,831
-123,138
-12% -$2.56M 0.03% 336
2026
Q1 		$23.1M Sell
990,969
-607,575
-38% -$13.2M 0.04% 284
2025
Q4 		$33.6M Buy
1,598,544
+789,480
+98% +$13.8M 0.06% 233
2025
Q3 		$12.4M Buy
809,064
+120,000
+17% +$1.57M 0.02% 408
2025
Q2 		$6.45M Hold
689,064
– – 0.01% 584
2025
Q1 		$8.47M Buy
689,064
+421,115
+157% +$5.94M 0.02% 507
2024
Q4 		$3.54M Sell
267,949
-93,876
-26% -$1.61M 0.01% 745
2024
Q3 		$6.97M Sell
361,825
-157,060
-30% -$3.24M 0.01% 542
2024
Q2 		$10.7M Buy
518,885
+4,033
+0.8% +$84.4K 0.02% 435
2024
Q1 		$12.3M Hold
514,852
– – 0.02% 414
2023
Q4 		$11.1M Hold
514,852
– – 0.02% 407
2023
Q3 		$7.48M Buy
514,852
+126,500
+33% +$2.39M 0.02% 464
2023
Q2 		$8.13M Buy
388,352
+152,982
+65% +$3.19M 0.02% 476
2023
Q1 		$4.97M Hold
235,370
– – 0.01% 567
2022
Q4 		$5.99M Buy
235,370
+24,002
+11% +$560K 0.01% 519
2022
Q3 		$5.08M Buy
211,368
+85,177
+67% +$1.91M 0.01% 523
2022
Q2 		$2.43M Buy
126,191
+65,454
+108% +$1.09M 0.01% 737
2022
Q1 		$1.05M Hold
60,737
– – ﹤0.01% 1171
2021
Q4 		$1.33M Sell
60,737
-137,865
-69% -$2.55M ﹤0.01% 1136
2021
Q3 		$3.8M Buy
198,602
+142,484
+254% +$2.37M 0.01% 769
2021
Q2 		$963K Hold
56,118
– – ﹤0.01% 1450
2021
Q1 		$1.25M Buy
56,118
+15,141
+37% +$342K ﹤0.01% 1334
2020
Q4 		$911K Hold
40,977
– – ﹤0.01% 1432
2020
Q3 		$604K Buy
40,977
+23,023
+128% +$351K ﹤0.01% 1480
2020
Q2 		$266K Buy
17,954
+6,345
+55% +$96.6K ﹤0.01% 1551
2020
Q1 		$127K Sell
11,609
-11,610
-50% -$109K ﹤0.01% 1566
2019
Q4 		$204K Buy
+23,219
New +$171K ﹤0.01% 1615

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Ensign Peak Advisors's SNDX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Syndax Pharmaceuticals (SNDX) stake by 12% in Q2 2026, selling an estimated $2.56M and leaving 867,831 shares worth $19M. The position accounts for 0.03% of the portfolio, ranked #336.

Ensign Peak Advisors first reported a position in SNDX in Q4 2019 and has held it in 27 quarters since. The position peaked at $33.6M in Q4 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Ensign Peak Advisors held 867,831 shares of Syndax Pharmaceuticals worth $19M as of Q2 2026.
  • Ensign Peak Advisors sold 123,138 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.56M.
  • Syndax Pharmaceuticals made up 0.03% of Ensign Peak Advisors's portfolio in Q2 2026, its #336 holding.
  • Ensign Peak Advisors first reported a position in Syndax Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's Syndax Pharmaceuticals position peaked at $33.6M in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.